APA
Schöffski P., Adkins D., Blay J., Gil T., Elias A. D., Rutkowski P., Pennock G. K., Youssoufian H., Gelderblom H., Willey R. & Grebennik D. O. (20140506). An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours. : European journal of cancer (Oxford, England : 1990).
Chicago
Schöffski P, Adkins D, Blay J-Y, Gil T, Elias A D, Rutkowski P, Pennock G K, Youssoufian H, Gelderblom H, Willey R and Grebennik D O. 20140506. An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours. : European journal of cancer (Oxford, England : 1990).
Harvard
Schöffski P., Adkins D., Blay J., Gil T., Elias A. D., Rutkowski P., Pennock G. K., Youssoufian H., Gelderblom H., Willey R. and Grebennik D. O. (20140506). An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours. : European journal of cancer (Oxford, England : 1990).
MLA
Schöffski P, Adkins D, Blay J-Y, Gil T, Elias A D, Rutkowski P, Pennock G K, Youssoufian H, Gelderblom H, Willey R and Grebennik D O. An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours. : European journal of cancer (Oxford, England : 1990). 20140506.